BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004;99:91-96. [PMID: 14687148 DOI: 10.1046/j.1572-0241.2003.04010.x] [Cited by in Crossref: 191] [Cited by in F6Publishing: 169] [Article Influence: 10.6] [Reference Citation Analysis]
Number Citing Articles
1 Müller C, Bergmann M, Stift A, Argeny S, Speake D, Unger L, Riss S. Restoration of intestinal continuity after stoma formation for Crohn’s disease in the era of biological therapy: A retrospective cohort study. Wien Klin Wochenschr 2020;132:12-8. [DOI: 10.1007/s00508-019-01586-9] [Reference Citation Analysis]
2 Abraham BP, Sellin JH. Disability in inflammatory bowel disease. Gastroenterol Clin North Am 2012;41:429-41. [PMID: 22500527 DOI: 10.1016/j.gtc.2012.02.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
3 Malone DC, Waters HC, Van Den Bos J, Popp J, Draaghtel K, Rahman MI. A claims-based Markov model for Crohn’s disease: Disease severity and costs in Crohn’s disease. Alimentary Pharmacology & Therapeutics 2010;32:448-58. [DOI: 10.1111/j.1365-2036.2010.04356.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
4 Siddiqui MAA, Scott LJ. Infliximab: A Review of its Use in Crohn???s Disease and Rheumatoid Arthritis. Drugs 2005;65:2179-208. [DOI: 10.2165/00003495-200565150-00014] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 3.6] [Reference Citation Analysis]
5 Lindsay J, Punekar YS, Morris J, Chung-Faye G. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease--modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther. 2008;28:76-87. [PMID: 18410558 DOI: 10.1111/j.1365-2036.2008.03709.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 4.5] [Reference Citation Analysis]
6 Xu Z, Davis HM, Zhou H. Rational development and utilization of antibody-based therapeutic proteins in pediatrics. Pharmacology & Therapeutics 2013;137:225-47. [DOI: 10.1016/j.pharmthera.2012.10.005] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
7 Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. A novel risk score to stratify severity of Crohn's disease hospitalizations. Am J Gastroenterol. 2010;105:1799-1807. [PMID: 20216534 DOI: 10.1038/ajg.2010.105] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
8 Frolkis AD, Dykeman J, Negrón ME, Debruyn J, Jette N, Fiest KM, Frolkis T, Barkema HW, Rioux KP, Panaccione R, Ghosh S, Wiebe S, Kaplan GG. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 2013;145:996-1006. [PMID: 23896172 DOI: 10.1053/j.gastro.2013.07.041] [Cited by in Crossref: 422] [Cited by in F6Publishing: 379] [Article Influence: 46.9] [Reference Citation Analysis]
9 Cottone M, Criscuoli V. Infliximab to treat Crohn's disease: an update. Clin Exp Gastroenterol 2011;4:227-38. [PMID: 22016584 DOI: 10.2147/CEG.S6440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
10 Casellas F, Rodrigo L, Niño P, Pantiga C, Riestra S, Malagelada JR. Sustained improvement of health-related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years. Inflamm Bowel Dis 2007;13:1395-400. [PMID: 17567874 DOI: 10.1002/ibd.20205] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
11 Bernstein CN. The Natural History of Inflammatory Bowel Disease. In: Baumgart DC, editor. Crohn's Disease and Ulcerative Colitis. Boston: Springer US; 2012. pp. 343-63. [DOI: 10.1007/978-1-4614-0998-4_26] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
12 Ferrante M, Vermeire S, Rutgeerts P. Certolizumab pegol in the treatment of Crohn's disease. Expert Opinion on Biological Therapy 2013;13:595-605. [DOI: 10.1517/14712598.2013.777039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
13 Takagi T, Arisawa T, Yamamoto K, Hirata I, Nakano H, Sawada M. IDENTIFICATION OF LIGANDS BINDING SPECIFICALLY TO INFLAMMATORY INTESTINAL MUCOSA USING PHAGE DISPLAY: Ligands binding to inflammatory bowel. Clinical and Experimental Pharmacology and Physiology 2007;34:286-9. [DOI: 10.1111/j.1440-1681.2007.04563.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
14 Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, Nissinen M, Rautiainen H, Kuisma J, Kolho K, Färkkilä M. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. Journal of Crohn's and Colitis 2013;7:730-5. [DOI: 10.1016/j.crohns.2012.10.018] [Cited by in Crossref: 73] [Cited by in F6Publishing: 72] [Article Influence: 8.1] [Reference Citation Analysis]
15 Timmer A, Kemptner D, Takses A, Klebl F, Jöckel K. A survey-based index was validated for measuring disease activity in inflammatory bowel disease. An evaluation study. Journal of Clinical Epidemiology 2009;62:771-8. [DOI: 10.1016/j.jclinepi.2008.07.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
16 Kaplan GG, Jess T. The Changing Landscape of Inflammatory Bowel Disease: East Meets West. Gastroenterology. 2016;150:24-26. [PMID: 26592321 DOI: 10.1053/j.gastro.2015.11.029] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
17 Moein S, Vaghari-Tabari M, Qujeq D, Kashifard M, Shokri-Shirvani J, Hajian-Tilaki K. Association between serum folate with inflammatory markers, disease clinical activity and serum homocysteine in patients with inflammatory bowel disease. Does folate level have an effect on maintaining clinical remission? Acta Biomed 2020;91:e2020106. [PMID: 33525287 DOI: 10.23750/abm.v91i4.8467] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Lichtenstein GR, Panaccione R, Mallarkey G. Efficacy and safety of adalimumab in Crohn’s disease. Therap Adv Gastroenterol. 2008;1:43-50. [PMID: 21180513 DOI: 10.1177/1756283x08092548] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
19 Gater A, Kitchen H, Heron L, Pollard C, Håkan-Bloch J, Højbjerre L, Hansen BB, Strandberg-Larsen M. Development of a conceptual model evaluating the humanistic and economic burden of Crohn's disease: implications for patient-reported outcomes measurement and economic evaluation. Expert Rev Pharmacoecon Outcomes Res 2015;15:643-56. [PMID: 25985850 DOI: 10.1586/14737167.2015.1045883] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
20 Miheller P, Kiss LS, Lorinczy K, Lakatos PL. Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use? Expert Opinion on Biological Therapy 2012;12:179-92. [DOI: 10.1517/14712598.2012.644271] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
21 Odes S. How expensive is inflammatory bowel disease? A critical analysis. World J Gastroenterol 2008; 14(43): 6641-6647 [PMID: 19034966 DOI: 10.3748/wjg.14.6641] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
22 Floyd DN, Langham S, Séverac HC, Levesque BG. The Economic and Quality-of-Life Burden of Crohn’s Disease in Europe and the United States, 2000 to 2013: A Systematic Review. Dig Dis Sci 2015;60:299-312. [DOI: 10.1007/s10620-014-3368-z] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 8.9] [Reference Citation Analysis]
23 Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics 2019;13:139-78. [PMID: 31440029 DOI: 10.2147/BTT.S207246] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
24 Buda A, Facchin S, Dassie E, Casarin E, Jepson MA, Neumann H, Hatem G, Realdon S, D’Incà R, Sturniolo GC. Detection of a fluorescent-labeled avidin-nucleic acid nanoassembly by confocal laser endomicroscopy in the microvasculature of chronically inflamed intestinal mucosa. Int J Nanomedicine. 2015;10:399-408. [PMID: 25609952 DOI: 10.2147/ijn.s70153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
25 Yu AP, Johnson S, Wang ST, Atanasov P, Tang J, Wu E, Chao J, Mulani PM. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn’s disease. Pharmacoeconomics. 2009;27:609-621. [PMID: 19663531 DOI: 10.2165/11312710-000000000-00000] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
26 Bastida G, Nos P, Aguas M, Beltrán B, Iborra M, Ortiz V, Garrigues V, Estevan R, Ponce J. The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients. BMC Gastroenterol. 2010;10:26. [PMID: 20196836 DOI: 10.1186/1471-230x-10-26] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
27 Scanlan PD, Shanahan F, Marchesi JR. Human methanogen diversity and incidence in healthy and diseased colonic groups using mcrA gene analysis. BMC Microbiol 2008;8:79. [PMID: 18492229 DOI: 10.1186/1471-2180-8-79] [Cited by in Crossref: 118] [Cited by in F6Publishing: 113] [Article Influence: 8.4] [Reference Citation Analysis]
28 Akobeng AK, Zhang D, Gordon M, MacDonald JK. Enteral nutrition for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2018;8:CD005984. [PMID: 30098021 DOI: 10.1002/14651858.CD005984.pub3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
29 Cohen RD. The pharmacoeconomics of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010;7:103-109. [PMID: 20134492 DOI: 10.1038/nrgastro.2009.232] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
30 Kaplan GG, Panaccione R, Hubbard JN, Nguyen GC, Shaheen AA, Ma C, Devlin SM, Leung Y, Myers RP. Inflammatory bowel disease patients who leave hospital against medical advice: predictors and temporal trends. Inflamm Bowel Dis 2009;15:845-51. [PMID: 19130616 DOI: 10.1002/ibd.20835] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
31 Boschetti G, Nancey S, Daniel F, Pariente B, Lerebours E, Duclos B, Bourreille A, Cadiot G, Fumery M, Moreau J, Marteau P, Bouhnik Y, Louis E, Flourié B; GETAID. Costs of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 Years. Inflamm Bowel Dis 2016;22:2924-32. [PMID: 27846194 DOI: 10.1097/MIB.0000000000000967] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
32 Blonski W, Buchner AM, Lichtenstein GR. Patient adherence and efficacy of certolizumab pegol in the management of Crohn's disease. Clin Med Insights Gastroenterol 2012;5:11-21. [PMID: 24833930 DOI: 10.4137/CGast.S7613] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
33 Feagan BG, Reilly MC, Gerlier L, Brabant Y, Brown M, Schreiber S. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study. Aliment Pharmacol Ther. 2010;31:1276-1285. [PMID: 20298497 DOI: 10.1111/j.1365-2036.2010.04303.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
34 Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn’s disease patients. Adv Therapy 2009;26:936-46. [DOI: 10.1007/s12325-009-0069-7] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 4.7] [Reference Citation Analysis]
35 Cabriada JL, Vera I, Domènech E, Barreiro-de Acosta M, Esteve M, Gisbert JP, Panés J, Gomollón F; Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). [Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]. Gastroenterol Hepatol 2013;36:127-46. [PMID: 23433780 DOI: 10.1016/j.gastrohep.2013.01.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
36 Marchetti M, Liberato NL, Di Sabatino A, Corazza GR. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease. Eur J Health Econ 2013;14:853-61. [PMID: 22975794 DOI: 10.1007/s10198-012-0430-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
37 Sussman DA, Kubiliun N, Mulani PM, Chao J, Gillis CA, Yang M, Lu M, T Abreu M. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS). Inflamm Bowel Dis 2012;18:2043-55. [PMID: 22241679 DOI: 10.1002/ibd.22873] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
38 Rieder F, Reinisch W. Thiopurines and the Natural Course of Crohn's Disease: Did We Finally Find the Right Therapeutic Target? American Journal of Gastroenterology 2014;109:1037-40. [DOI: 10.1038/ajg.2014.162] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
39 Buchanan J, Wordsworth S, Ahmad T, Perrin A, Vermeire S, Sans M, Taylor J, Jewell D. Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers. J Crohns Colitis 2011;5:301-16. [PMID: 21683300 DOI: 10.1016/j.crohns.2011.02.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
40 Sorrentino D, Avellini C, Geraci M, Dassopoulos T, Zarifi D, Vadalaʼ di Prampero SF, Benevento G. Tissue studies in screened first-degree relatives reveal a distinct Crohn's disease phenotype. Inflamm Bowel Dis 2014;20:1049-56. [PMID: 24788221 DOI: 10.1097/MIB.0000000000000051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
41 Cohen RD, Thomas T. Economics of the use of biologics in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am. 2006;35:867-882. [PMID: 17129818 DOI: 10.1016/j.gtc.2006.09.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
42 De La Rue SA, Bickston SJ. Evidence-based medications for the treatment of the inflammatory bowel diseases: . Current Opinion in Gastroenterology 2006;22:365-9. [DOI: 10.1097/01.mog.0000231809.10773.c7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
43 Reinisch W, Sandborn WJ, Bala M, Yan S, Feagan BG, Rutgeerts P, Radford-Smith G, Xu S, Eisenberg D, Olson A, Colombel JF. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis 2007;13:1135-40. [PMID: 17476675 DOI: 10.1002/ibd.20165] [Cited by in Crossref: 72] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
44 Valizadeh N, Murray AC, Suradkar K, Al-Mazrou A, Kiran RP. Impact of preoperative steroid or immunosuppressant use on short-term outcomes following colectomy in Crohn's disease patients. Tech Coloproctol 2017;21:217-23. [PMID: 28205051 DOI: 10.1007/s10151-017-1591-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
45 Büsch K, da Silva SA, Holton M, Rabacow FM, Khalili H, Ludvigsson JF. Sick leave and disability pension in inflammatory bowel disease: a systematic review. J Crohns Colitis. 2014;8:1362-1377. [PMID: 25001582 DOI: 10.1016/j.crohns.2014.06.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
46 Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. Physician density and hospitalization for inflammatory bowel disease. Inflamm Bowel Dis 2011;17:633-8. [PMID: 20848540 DOI: 10.1002/ibd.21357] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
47 Park KT, Bass D. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. Inflamm Bowel Dis. 2011;17:1603-1609. [PMID: 21053357 DOI: 10.1002/ibd.21488] [Cited by in Crossref: 89] [Cited by in F6Publishing: 94] [Article Influence: 7.4] [Reference Citation Analysis]
48 Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244 [PMID: 17876895 DOI: 10.3748/wjg.v13.i39.5238] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
49 Lorinczy K, Miheller P, Kiss SL, Lakatos PL. [Epidemiology, predictors and clinical aspects of loss of response to biological therapy]. Orv Hetil 2012;153:163-73. [PMID: 22275731 DOI: 10.1556/OH.2012.29294] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
50 Gibson PR, Weston AR, Shann A, Florin TH, Lawrance IC, Macrae FA, Radford-Smith G. Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn's disease. J Gastroenterol Hepatol. 2007;22:1306-1312. [PMID: 17559375 DOI: 10.1111/j.1440-1746.2007.04930.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 2.7] [Reference Citation Analysis]
51 Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Sparrow MP, Florin TH, Gibson PR, Debinski H, Gearry RB, Macrae FA, Leong RW, Kronborg I, Radford-smith G, Selby W, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Desmond PV. Effect of Intestinal Resection on Quality of Life in Crohn's Disease. Journal of Crohn's and Colitis 2015;9:452-62. [DOI: 10.1093/ecco-jcc/jjv058] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
52 Bourgonje AR, von Martels JZH, Gabriëls RY, Blokzijl T, Buist-Homan M, Heegsma J, Jansen BH, van Dullemen HM, Festen EAM, Ter Steege RWF, Visschedijk MC, Weersma RK, de Vos P, Faber KN, Dijkstra G. A Combined Set of Four Serum Inflammatory Biomarkers Reliably Predicts Endoscopic Disease Activity in Inflammatory Bowel Disease. Front Med (Lausanne) 2019;6:251. [PMID: 31772929 DOI: 10.3389/fmed.2019.00251] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
53 Saro C, da la Coba C, Casado MA, Morales JM, Otero B. Resource use in patients with Crohn's disease treated with infliximab. Aliment Pharmacol Ther. 2007;26:1313-1323. [PMID: 17850419 DOI: 10.1111/j.1365-2036.2007.03507.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
54 Sellin JH. Deconstructing Disability in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2014;12:1338-41. [DOI: 10.1016/j.cgh.2014.02.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
55 Abraham NS, Richardson P, Castillo D, Kane S. WITHDRAWN: Dual Therapy With Infliximab and Immunomodulator Reduces 1-Year Rates of Hospitalization and Surgery Among Veterans With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2013:S1542-3565(13)01042-2. [PMID: 23891919 DOI: 10.1016/j.cgh.2013.04.051] [Reference Citation Analysis]
56 Ganz ML, Sugarman R, Wang R, Hansen BB, Håkan-Bloch J. The Economic and Health-related Impact of Crohn's Disease in the United States: Evidence from a Nationally Representative Survey. Inflamm Bowel Dis 2016;22:1032-41. [PMID: 26974852 DOI: 10.1097/MIB.0000000000000742] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
57 Johnson SL, Palta M, Bartels CM, Thorpe CT, Weiss JM, Smith MA. Examining systemic steroid Use in older inflammatory bowel disease patients using hurdle models: a cohort study. BMC Pharmacol Toxicol 2015;16:34. [PMID: 26643112 DOI: 10.1186/s40360-015-0034-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
58 Bodger K. Cost Effectiveness of Treatments for Inflammatory Bowel Disease: . PharmacoEconomics 2011;29:387-401. [DOI: 10.2165/11584820-000000000-00000] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
59 Bourgonje AR, Feelisch M, Faber KN, Pasch A, Dijkstra G, van Goor H. Oxidative Stress and Redox-Modulating Therapeutics in Inflammatory Bowel Disease. Trends Mol Med 2020;26:1034-46. [PMID: 32620502 DOI: 10.1016/j.molmed.2020.06.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
60 Casellas F, Ginard D, Vera I, Torrejón A. Satisfaction of health care professionals managing patients with inflammatory bowel disease. Journal of Crohn's and Colitis 2013;7:e249-55. [DOI: 10.1016/j.crohns.2012.10.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
61 Caviglia R, Boškoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opinion on Drug Safety 2008;7:617-32. [DOI: 10.1517/14740338.7.5.617] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
62 Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Naim A, Lofland JH. The Employee Absenteeism Costs of Inflammatory Bowel Disease: Evidence From US National Survey Data. Journal of Occupational & Environmental Medicine 2013;55:393-401. [DOI: 10.1097/jom.0b013e31827cba48] [Cited by in Crossref: 23] [Cited by in F6Publishing: 5] [Article Influence: 2.6] [Reference Citation Analysis]
63 Targownik LE, Benchimol EI, Witt J, Bernstein CN, Singh H, Lix L, Tennakoon A, Zubieta AA, Coward S, Jones J, Kuenzig E, Murthy SK, Nguyen GC, Peña-Sánchez JN, Kaplan G. The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1718-28. [PMID: 31211836 DOI: 10.1093/ibd/izz063] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
64 Zand A, van Deen WK, Inserra EK, Hall L, Kane E, Centeno A, Choi JM, Ha CY, Esrailian E, DʼHaens GR, Hommes DW. Presenteeism in Inflammatory Bowel Diseases: A Hidden Problem with Significant Economic Impact. Inflamm Bowel Dis 2015;21:1623-30. [PMID: 26070004 DOI: 10.1097/MIB.0000000000000399] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
65 Calvet X, Gallardo O, Coronas R, Casellas F, Montserrat A, Torrejón A, Vergara M, Campo R, Brullet E. Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn’s disease. Inflamm Bowel Dis. 2006;12:692-696. [PMID: 16917223 DOI: 10.1097/00054725-200608000-00004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
66 Hyams JS, Markowitz JF. Can we alter the natural history of Crohn disease in children? J Pediatr Gastroenterol Nutr 2005;40:262-72. [PMID: 15735477 DOI: 10.1097/01.mpg.0000154660.62359.fe] [Cited by in Crossref: 27] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
67 Schaffer T, Schoepfer AM, Seibold F; Swiss IBD Cohort Study Group. Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity. J Crohns Colitis 2014;8:1125-32. [PMID: 24636141 DOI: 10.1016/j.crohns.2014.02.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
68 Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-1231. [PMID: 17229796 DOI: 10.1136/gut.2006.099978] [Cited by in Crossref: 419] [Cited by in F6Publishing: 387] [Article Influence: 27.9] [Reference Citation Analysis]
69 Barello S, Guida E, Leone S, Previtali E, Graffigna G. Does patient engagement affect IBD patients' health-related quality of life? Findings from a cross-sectional study among people with inflammatory bowel diseases. Health Qual Life Outcomes 2021;19:77. [PMID: 33678181 DOI: 10.1186/s12955-021-01724-w] [Reference Citation Analysis]
70 Nugent Z, Blanchard JF, Bernstein CN. A Population-Based Study of Health-Care Resource Use Among Infliximab Users. American Journal of Gastroenterology 2010;105:2009-16. [DOI: 10.1038/ajg.2010.139] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
71 Ye BD, Yang S, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim Y, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Guidelines for the Management of Crohn's Disease. Intest Res 2012;10:26. [DOI: 10.5217/ir.2012.10.1.26] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
72 Artz N, Zhang J, Meltzer D. Physical and Mental Health in Adults Hospitalized with Sickle Cell Disease: Impact on Resource Use. Journal of the National Medical Association 2009;101:139-44. [DOI: 10.1016/s0027-9684(15)30826-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
73 Kemp K, Campbell S. Patient choice in administering anti-TNF for severe, active Crohn's disease in adults. Gastrointestinal Nursing 2009;7:16-22. [DOI: 10.12968/gasn.2009.7.10.45663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
74 D’Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199-212; quiz 213. [PMID: 21045814 DOI: 10.1038/ajg.2010.392] [Cited by in Crossref: 263] [Cited by in F6Publishing: 256] [Article Influence: 21.9] [Reference Citation Analysis]
75 Akobeng AK, Thomas AG. Enteral nutrition for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2007;CD005984. [PMID: 17636816 DOI: 10.1002/14651858.cd005984.pub2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
76 Vergara M, Montserrat A, Casellas F, Gallardo O, Suarez D, Motos J, Villoria A, Miquel M, Martinez-bauer E, Calvet X. Development and validation of the Crohnʼs disease perceived work disability questionnaire: . Inflammatory Bowel Diseases 2011;17:2350-7. [DOI: 10.1002/ibd.21604] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
77 Bordeianou L, Kunitake H, Shellito P, Hodin R. Preoperative infliximab treatment in patients with ulcerative and indeterminate colitis does not increase rate of conversion to emergent and multistep abdominal surgery. Int J Colorectal Dis 2010;25:401-4. [DOI: 10.1007/s00384-009-0800-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
78 Tang DH, Harrington AR, Lee JK, Lin M, Armstrong EP. A Systematic Review of Economic Studies on Biological Agents Used to Treat Crohn’s Disease: . Inflammatory Bowel Diseases 2013;19:2673-94. [DOI: 10.1097/mib.0b013e3182916046] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
79 Steinhart AH, Forbes A, Mills EC, Rodgers-Gray BS, Travis SP. Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2007;25:1389-99. [PMID: 17539978 DOI: 10.1111/j.1365-2036.2007.03324.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
80 Boon GJ, Day AS, Mulder CJ, Gearry RB. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease? World J Gastroenterol 2015; 21(40): 11469-11480 [PMID: 26523111 DOI: 10.3748/wjg.v21.i40.11469] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
81 Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis: STRATEGIES FOR LOSS OF RESPONSE TO INFLIXIMAB IN CD. Alimentary Pharmacology & Therapeutics 2007;26:1509-20. [DOI: 10.1111/j.1365-2036.2007.03548.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 4.5] [Reference Citation Analysis]
82 Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-assi SG. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohnʼs disease: . Inflammatory Bowel Diseases 2010;16:962-73. [DOI: 10.1002/ibd.21117] [Cited by in Crossref: 86] [Cited by in F6Publishing: 79] [Article Influence: 7.2] [Reference Citation Analysis]
83 Ruiz MA, Kaiser RL Jr, de Quadros LG, Piron-Ruiz L, Peña-Arciniegas T, Faria MAG, Siqueira RC, Pirozzi FF, Kaiser FSL, Burt RK. Low toxicity and favorable clinical and quality of life impact after non-myeloablative autologous hematopoietic stem cell transplant in Crohn's disease. BMC Res Notes 2017;10:495. [PMID: 28985769 DOI: 10.1186/s13104-017-2824-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
84 Sorrentino D, Fogel S, Van den Bogaerde J. Surgery for Crohn’s disease and anti-TNF agents: the changing scenario. Expert Rev Gastroenterol Hepatol. 2013;7:689-700. [PMID: 24161133 DOI: 10.1586/17474124.2013.842895] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
85 Teich N, Bläker M, Holtkamp-Endemann F, Jörgensen E, Stallmach A, Hohenberger S. Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn's Disease in a Real-Life Setting: Results of a Prospective Multicenter Study in Germany. Inflamm Intest Dis 2021;6:48-60. [PMID: 33850839 DOI: 10.1159/000512159] [Reference Citation Analysis]
86 Wright EK, Kamm MA. Impact of Drug Therapy and Surgery on Quality of Life in Crohnʼs Disease: A Systematic Review. Inflammatory Bowel Diseases 2015;21:1187-94. [DOI: 10.1097/mib.0000000000000271] [Cited by in Crossref: 45] [Cited by in F6Publishing: 12] [Article Influence: 6.4] [Reference Citation Analysis]
87 Ye BD, Yang SK, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim YH, Lee H. [Guidelines for the management of Crohn’s disease]. Korean J Gastroenterol. 2012;59:141-179. [PMID: 22387837 DOI: 10.4166/kjg.2012.59.2.141] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
88 Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol 2009;104:1170-9. [PMID: 19352339 DOI: 10.1038/ajg.2009.59] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 4.6] [Reference Citation Analysis]
89 Astegiano M, Pagano N, Sapone N, Simondi D, Bertolusso L, Bresso F, Demarchi B, Pellicano R, Bonardi R, Marconi S, Rizzetto M. Efficacy and safety of oral beclomethasone dipropionate for ileal or ileal-right colon Crohn's disease of mild-to-moderate activity or in remission: Retrospective study. Biomedicine & Pharmacotherapy 2007;61:370-6. [DOI: 10.1016/j.biopha.2007.02.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
90 Sellin J. Disability in IBD: The devil is in the details: . Inflammatory Bowel Diseases 2010;16:23-6. [DOI: 10.1002/ibd.21014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
91 Ahmed Z, Sarvepalli S, Garber A, Regueiro M, Rizk MK. Value-Based Health Care in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2019;25:958-68. [DOI: 10.1093/ibd/izy340] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
92 Ananthakrishnan AN, Korzenik JR, Hur C. Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis. Inflamm Bowel Dis. 2013;19:37-44. [PMID: 22416019 DOI: 10.1002/ibd.22951] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
93 Casellas i Jordà F. [TNF-alpha inhibitors in inflammatory bowel disease]. Med Clin (Barc) 2004;123:627-34. [PMID: 15546523 DOI: 10.1016/s0025-7753(04)74622-9] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
94 Mir Viladrich I, Daudén Tello E, Solano-López G, López Longo FJ, Taxonera Samso C, Sánchez Martínez P, Martínez Lacasa X, García Gasalla M, Dorca Sargatal J, Arias-Guillén M, García García JM. Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment. Arch Bronconeumol 2016;52:36-45. [PMID: 26187708 DOI: 10.1016/j.arbres.2015.04.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 3.9] [Reference Citation Analysis]
95 Casellas F, Arenas JI, Baudet JS, Fábregas S, García N, Gelabert J, Medina C, Ochotorena I, Papo M, Rodrigo L, Malagelada JR. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005;11:488-96. [PMID: 15867589 DOI: 10.1097/01.mib.0000159661.55028.56] [Cited by in Crossref: 183] [Cited by in F6Publishing: 60] [Article Influence: 10.8] [Reference Citation Analysis]
96 Huoponen S, Blom M. A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases. PLoS One 2015;10:e0145087. [PMID: 26675292 DOI: 10.1371/journal.pone.0145087] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
97 Gearry RB, Irving PM. Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to? J Gastroenterol Hepatol 2009;24:1160-2. [PMID: 19682189 DOI: 10.1111/j.1440-1746.2009.05896.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
98 Rogers CC, Moutinho TJ Jr, Liu X, Valdez RS. Designing Consumer Health Information Technology to Support Biform and Articulation Work: A Qualitative Study of Diet and Nutrition Management as Patient Work. JMIR Hum Factors 2021;8:e27452. [PMID: 34383664 DOI: 10.2196/27452] [Reference Citation Analysis]
99 Chen J. Mesalamine-induced nephrotoxicity in the treatment of Crohn disease: a case study. Gastroenterol Nurs 2014;37:70-3. [PMID: 24476836 DOI: 10.1097/SGA.0000000000000026] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
100 Schoepfer AM, Vavricka S, Zahnd-straumann N, Straumann A, Beglinger C. Monitoring inflammatory bowel disease activity: Clinical activity is judged to be more relevant than endoscopic severity or biomarkers. Journal of Crohn's and Colitis 2012;6:412-8. [DOI: 10.1016/j.crohns.2011.09.008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
101 Sarid O, Slonim-Nevo V, Sergienko R, Pereg A, Chernin E, Singer T, Greenberg D, Schwartz D, Vardi H, Friger M, Odes S. Daily hassles score associates with the somatic and psychological health of patients with Crohn's disease. J Clin Psychol 2018;74:969-88. [PMID: 29244192 DOI: 10.1002/jclp.22561] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
102 Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162-169. [PMID: 19755969 DOI: 10.1038/ajg.2009.545] [Cited by in Crossref: 344] [Cited by in F6Publishing: 317] [Article Influence: 26.5] [Reference Citation Analysis]
103 Israeli E, Graff LA, Clara I, Walker JR, Lix LM, Targownik LE, Bernstein CN. Low prevalence of disability among patients with inflammatory bowel diseases a decade after diagnosis. Clin Gastroenterol Hepatol 2014;12:1330-7.e2. [PMID: 24361416 DOI: 10.1016/j.cgh.2013.12.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
104 Lightner AL, Pemberton JH, Dozois EJ, Larson DW, Cima RR, Mathis KL, Pardi DS, Andrew RE, Koltun WA, Sagar P, Hahnloser D. The surgical management of inflammatory bowel disease. Curr Probl Surg 2017;54:172-250. [PMID: 28576304 DOI: 10.1067/j.cpsurg.2017.02.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
105 Panaccione R, Colombel JF, Travis SPL, Bossuyt P, Baert F, Vaňásek T, Danalıoğlu A, Novacek G, Armuzzi A, Reinisch W, Johnson S, Buessing M, Neimark E, Petersson J, Lee WJ, D'Haens GR. Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. Gut 2020;69:658-64. [PMID: 31285357 DOI: 10.1136/gutjnl-2019-318256] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
106 Bodger K. Economic implications of biological therapies for Crohn's disease: review of infliximab. Pharmacoeconomics 2005;23:875-88. [PMID: 16153132 DOI: 10.2165/00019053-200523090-00002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
107 Vogelaar L, Spijker AV, van der Woude CJ. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. Clin Exp Gastroenterol. 2009;2:101-109. [PMID: 21694833 DOI: 10.2147/ceg.s4512] [Cited by in Crossref: 43] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
108 Colombel J. Efficacy and safety of adalimumab for the treatment of Crohn’s disease in adults. Expert Review of Gastroenterology & Hepatology 2014;2:163-76. [DOI: 10.1586/17474124.2.2.163] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
109 Af Björkesten CG, Jussila A, Kemppainen H, Hallinen T, Soini E, Mankinen P, Valgarðsson S, Veckman V, Nissinen R, Naessens D, Molander P. Relationship of faecal calprotectin and long-term outcomes in Finnish patients with Crohn's disease: retrospective multi-centre chart review study. Scand J Gastroenterol 2019;54:1226-32. [PMID: 31532265 DOI: 10.1080/00365521.2019.1667426] [Reference Citation Analysis]
110 Siegel CA, Levy LC, Mackenzie TA, Sands BE. Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1-6. [PMID: 17924559 DOI: 10.1002/ibd.20283] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
111 Boktor M, Motlis A, Aravantagi A, Sheth A, Jordan P, Morris J, Manas K, Hussain N, Cvek U, Trutschl M, Becker F, Alexander JS. Substitution with Alternative Anti-TNFα Therapy (SAVANT)-Outcomes of a Crohn's Disease Cohort Undergoing Substitution Therapy with Certolizumab. Inflamm Bowel Dis 2016;22:1353-61. [PMID: 27104819 DOI: 10.1097/MIB.0000000000000765] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
112 Petryszyn PW, Paradowski L. Economic implications of biological therapy for Crohn's disease. Prz Gastroenterol 2015;10:197-202. [PMID: 26759625 DOI: 10.5114/pg.2015.55749] [Reference Citation Analysis]
113 Behm BW, Bickston SJ. Efficacy of infliximab for luminal and fistulizing Crohn's disease and in ulcerative colitis. Curr Treat Options Gastroenterol. 2007;10:171-177. [PMID: 17547855 DOI: 10.1007/s11938-007-0010-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
114 Juillerat P, Wasan SK, Fowler SA, Friedman S, Pabby VK, Coukas JA, Barto AE, Pellish R, Germansky KA, Cheifetz AS, Korzenik JR, Farraye FA, Yajnik V. Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals. Inflamm Bowel Dis 2013;19:2457-63. [PMID: 23962896 DOI: 10.1097/MIB.0b013e3182a32a0d] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
115 Ollendorf DA, Lidsky L. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting. Am J Ther 2006;13:502-6. [PMID: 17122530 DOI: 10.1097/01.mjt.0000245223.43783.45] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
116 Jauregui-Amezaga A, Rimola J, Ordás I, Rodríguez S, Ramírez-Morros A, Gallego M, Masamunt MC, Llach J, González-Suárez B, Ricart E. Value of endoscopy and MRI for predicting intestinal surgery in patients with Crohn’s disease in the era of biologics. Gut. 2015;64:1397-1402. [PMID: 25516418 DOI: 10.1136/gutjnl-2014-308101] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 6.6] [Reference Citation Analysis]
117 Geltzeiler CB, Hart KD, Lu KC, Deveney KE, Herzig DO, Tsikitis VL. Trends in the Surgical Management of Crohn's Disease. J Gastrointest Surg 2015;19:1862-8. [PMID: 26286366 DOI: 10.1007/s11605-015-2911-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
118 Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104:465-83; quiz 464, 484. [PMID: 19174807 DOI: 10.1038/ajg.2008.168] [Cited by in Crossref: 606] [Cited by in F6Publishing: 516] [Article Influence: 46.6] [Reference Citation Analysis]
119 Wolf DC, Jaganathan S, Burudpakdee C, Seetasith A, Low R, Lee E, Gucky J, Yassine M, Schwartz DA. Adherence rates and health care costs in Crohn's disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data. Patient Prefer Adherence 2018;12:869-78. [PMID: 29872272 DOI: 10.2147/PPA.S148777] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
120 Rice SA, Woo PN, El-Omar E, Keenan RA, Ormerod AD. Topical tacrolimus 0.1% ointment for treatment of cutaneous Crohn's Disease. BMC Res Notes 2013;6:19. [PMID: 23331739 DOI: 10.1186/1756-0500-6-19] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
121 Nguyen GC, Tuskey A, Dassopoulos T, Harris ML, Brant SR. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis. 2007;13:1529-1535. [PMID: 17828784 DOI: 10.1002/ibd.20250] [Cited by in Crossref: 109] [Cited by in F6Publishing: 109] [Article Influence: 7.8] [Reference Citation Analysis]
122 Zisman TL, Cohen RD. Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease. Curr Treat Options Gastro 2007;10:185-94. [DOI: 10.1007/s11938-007-0012-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
123 Di Sabatino A, Liberato L, Marchetti M, Biancheri P, Corazza GR. Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease. Intern Emerg Med. 2011;6 Suppl 1:17-27. [PMID: 22009609 DOI: 10.1007/s11739-011-0673-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
124 Feagan BG, Lémann M, Befrits R, Connell W, Dʼhaens G, Ghosh S, Michetti P, Ochsenkühn T, Panaccione R, Schreiber S, Silverberg M, Sorrentino D, van der Woude JC, Vermeire S, Rutgeerts P. Recommendations for the treatment of Crohnʼs disease with tumor necrosis factor antagonists: An expert consensus report: . Inflammatory Bowel Diseases 2012;18:152-60. [DOI: 10.1002/ibd.21870] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
125 Chia AYT, Ang GWX, Chan ASY, Chan W, Chong TKY, Leung YY. Managing Psoriatic Arthritis With Inflammatory Bowel Disease and/or Uveitis. Front Med (Lausanne) 2021;8:737256. [PMID: 34604268 DOI: 10.3389/fmed.2021.737256] [Reference Citation Analysis]
126 Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Lomax KG, Yu AP, Wu EQ. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008;135:1493-1499. [PMID: 18848553 DOI: 10.1053/j.gastro.2008.07.069] [Cited by in Crossref: 248] [Cited by in F6Publishing: 226] [Article Influence: 17.7] [Reference Citation Analysis]
127 Maier LA, Barkes BQ, Mroz M, Rossman MD, Barnard J, Gillespie M, Martin A, Mack DG, Silveira L, Sawyer RT, Newman LS, Fontenot AP. Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease. Respir Med 2012;106:1810-3. [PMID: 22974830 DOI: 10.1016/j.rmed.2012.08.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
128 Behm BW, Bickston SJ. Medical management of Crohn's disease: current therapy and recent advances. Expert Review of Clinical Immunology 2014;2:109-20. [DOI: 10.1586/1744666x.2.1.109] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
129 Ueno F, Doi M, Kawai Y, Ukawa N, Cammarota J, Betts KA. Number needed to treat and cost per remitter for biologic treatments of Crohn’s disease in Japan. Journal of Medical Economics 2020;23:80-5. [DOI: 10.1080/13696998.2019.1642900] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
130 Vester-andersen MK, Prosberg MV, Vind I, Andersson M, Jess T, Bendtsen F. Low Risk of Unemployment, Sick Leave, and Work Disability Among Patients with Inflammatory Bowel Disease: A 7-year Follow-up Study of a Danish Inception Cohort. Inflammatory Bowel Diseases 2015. [DOI: 10.1097/mib.0000000000000493] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
131 Demase DF, Gruenthal M, Balint J. The national temporal lobectomy survey. Seizure 2009;18:702-10. [DOI: 10.1016/j.seizure.2009.10.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
132 Han SW, McColl E, Barton JR, James P, Steen IN, Welfare MR. Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. Inflamm Bowel Dis. 2005;11:24-34. [PMID: 15674110 DOI: 10.1097/00054725-200501000-00004] [Cited by in Crossref: 95] [Cited by in F6Publishing: 90] [Article Influence: 5.6] [Reference Citation Analysis]
133 Leung Y, Hanauer S. Conventional treatment in inflammatory bowel disease- recent trends. Immunosuppressants and biologic agents: should they or need they be used together? Gastroentérologie Clinique et Biologique 2009;33:S202-8. [DOI: 10.1016/s0399-8320(09)73155-0] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
134 Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther. 2011;5:185-210. [PMID: 21552489 DOI: 10.2147/dddt.s11290] [Cited by in Crossref: 137] [Cited by in F6Publishing: 76] [Article Influence: 12.5] [Reference Citation Analysis]
135 Panaccione R, Colombel JF, Sandborn WJ, Rutgeerts P, D’Haens GR, Robinson AM, Chao J, Mulani PM, Pollack PF. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease. Aliment Pharmacol Ther. 2010;31:1296-1309. [PMID: 20298496 DOI: 10.1111/j.1365-2036.2010.04304.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 5.6] [Reference Citation Analysis]
136 Kim HJ, Kim Y, Cho JM, Oh SH, Kim KM. Therapeutic Efficacy of Oral Enteral Nutrition in Pediatric Crohn's Disease: A Single Center Non-Comparative Retrospective Study. Yonsei Med J 2016;57:1185-91. [PMID: 27401650 DOI: 10.3349/ymj.2016.57.5.1185] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
137 Loomes DE, Teshima C, Jacobs P, Fedorak RN. Health care resource use and costs in Crohn’s disease before and after infliximab therapy. Can J Gastroenterol. 2011;25:497-502. [PMID: 21912761 DOI: 10.1155/2011/157604] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
138 Dignass A, Van Assche G, Lindsay J, Lémann M, Söderholm J, Colombel J, Danese S, D'hoore A, Gassull M, Gomollón F, Hommes D, Michetti P, O'morain C, Öresland T, Windsor A, Stange E, Travis S. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. Journal of Crohn's and Colitis 2010;4:28-62. [DOI: 10.1016/j.crohns.2009.12.002] [Cited by in Crossref: 981] [Cited by in F6Publishing: 886] [Article Influence: 81.8] [Reference Citation Analysis]
139 Gonvers J, Juillerat P, Mottet C, Pittet V, Felley C, Vader J, Michetti P, Froehlich F. Maintenance of Medically Induced Remission of Crohn’s Disease. Digestion 2008;76:116-29. [DOI: 10.1159/000111026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
140 van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, Pierik M, van der Woude CJ, Romberg-Camps MJ. Risk factors of work disability in patients with inflammatory bowel disease--a Dutch nationwide web-based survey: work disability in inflammatory bowel disease. J Crohns Colitis. 2014;8:590-597. [PMID: 24351733 DOI: 10.1016/j.crohns.2013.11.019] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
141 Riis A, Martinsen TC, Waldum HL, Fossmark R. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease. Scand J Gastroenterol. 2012;47:649-657. [PMID: 22472026 DOI: 10.3109/00365521.2012.672591] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
142 Abraham NS, Richardson P, Castillo D, Kane SV. Dual Therapy With Infliximab and Immunomodulator Reduces One-Year Rates of Hospitalization and Surgery Among Veterans With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2013;11:1281-7. [DOI: 10.1016/j.cgh.2013.06.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
143 Spekhorst LM, Oldenburg B, van Bodegraven AA, de Jong DJ, Imhann F, van der Meulen-de Jong AE, Pierik MJ, van der Woude JC, Dijkstra G, D’Haens G, Löwenberg M, Weersma RK, Festen EAM, Parelsnoer Institute and the Dutch Initiative on Crohn and Colitis. Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease. World J Gastroenterol 2017; 23(46): 8182-8192 [PMID: 29290654 DOI: 10.3748/wjg.v23.i46.8182] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
144 Feagan BG, Sandborn WJ, Wolf DC, Coteur G, Purcaru O, Brabant Y, Rutgeerts PJ. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab: Randomised clinical trial: certolizumab health outcome in Crohn’s disease. Alimentary Pharmacology & Therapeutics 2011;33:541-50. [DOI: 10.1111/j.1365-2036.2010.04568.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
145 Chen JM, He LW, Yan T, Guo XF, Hu PJ, Peng JS, Cheng WJ, Li LL, He Q. Oral exclusive enteral nutrition induces mucosal and transmural healing in patients with Crohn's disease. Gastroenterol Rep (Oxf). 2019;7:176-184. [PMID: 31217981 DOI: 10.1093/gastro/goy050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 van Langenberg DR, Simon SB, Holtmann GJ, Andrews JM. The burden of inpatient costs in inflammatory bowel disease and opportunities to optimize care: a single metropolitan Australian center experience. J Crohns Colitis. 2010;4:413-421. [PMID: 21122537 DOI: 10.1016/j.crohns.2010.01.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
147 Rieder F, Kugathasan S. Circulating antibodies against bacterial wall products: are there arguments for early immunosuppression? Dig Dis. 2012;30 Suppl 3:55-66. [PMID: 23295693 DOI: 10.1159/000342603] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
148 Taxonera C, Rodrigo L, Casellas F, Calvet X, Gómez-Camacho F, Ginard D, Castro M, Castro L, Ponce M, Martínez-Montiel P, Ricart E, Gisbert JP, López-San Román A, Morales JM, Casado MA. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease. J Clin Gastroenterol 2009;43:950-6. [PMID: 19448569 DOI: 10.1097/MCG.0b013e3181986917] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
149 Huh G, Yoon H, Choi YJ, Shin CM, Park YS, Kim N, Lee DH, Kim JS. Trends in emergency department visits and hospitalization rates for inflammatory bowel disease in the era of biologics. PLoS One 2019;14:e0210703. [PMID: 30650133 DOI: 10.1371/journal.pone.0210703] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
150 Ferrante M, Vermeire S, Rutgeerts PJ. Drug safety evaluation of certolizumab pegol. Expert Opin Drug Saf 2014;13:255-66. [PMID: 24156537 DOI: 10.1517/14740338.2014.851666] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
151 Shelton E, Chaudrey K, Sauk J, Khalili H, Masia R, Nguyen DD, Yajnik V, Ananthakrishnan AN. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41:972-979. [PMID: 25756190 DOI: 10.1111/apt.13159] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
152 Akobeng AK, Gardener E, Akobeng AK. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd003715.pub2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
153 Chen H, Shi J, Pan Y, Zhang Z, Fang H, Chen Y, Chen W, Cao Q. Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn’s Disease in China. Adv Ther 2020;37:431-49. [DOI: 10.1007/s12325-019-01150-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
154 Akobeng AK, Zhang D, Gordon M, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database Syst Rev. 2016;9:CD003715. [PMID: 27681657 DOI: 10.1002/14651858.cd003715.pub3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
155 Thomas T, Cohen RD. Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies. Expert Review of Gastroenterology & Hepatology 2014;1:101-12. [DOI: 10.1586/17474124.1.1.101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
156 Alters SE, McLaughlin B, Spink B, Lachinyan T, Wang CW, Podust V, Schellenberger V, Stemmer WP. GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model. PLoS One 2012;7:e50630. [PMID: 23189208 DOI: 10.1371/journal.pone.0050630] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
157 Allaire S, Wolfe F, Niu J, Zhang Y, Zhang B, LaValley M. Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out. Arthritis Rheum 2008;59:1082-9. [PMID: 18668597 DOI: 10.1002/art.23923] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
158 Gionchetti P, Rizzello F, Annese V, Armuzzi A, Biancone L, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Incà R, Fries W, Kohn A, Orlando A, Papi C, Vecchi M, Ardizzone S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease.Dig Liver Dis. 2017;49:604-617. [PMID: 28254463 DOI: 10.1016/j.dld.2017.01.161] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
159 Jackson JF, Kornbluth A. Do Black and Hispanic Americans With Inflammatory Bowel Disease (IBD) Receive Inferior Care Compared With White Americans? Uneasy Questions and Speculations. Am J Gastroenterology 2007;102:1343-9. [DOI: 10.1111/j.1572-0241.2007.01371.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
160 Rutgeerts P, Gasink C, Chan D, Lang Y, Pollack P, Colombel JF, Wolf DC, Jacobstein D, Johanns J, Szapary P, Adedokun OJ, Feagan BG, Sandborn WJ. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. Gastroenterology 2018;155:1045-58. [PMID: 29909019 DOI: 10.1053/j.gastro.2018.06.035] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 16.3] [Reference Citation Analysis]
161 Devlin SM, Panaccione R. Adalimumab for the treatment of Crohn's disease. Expert Opin Biol Ther 2008;8:1011-9. [PMID: 18549330 DOI: 10.1517/14712598.8.7.1011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
162 Panaccione R, Loftus EV Jr, Binion D, McHugh K, Alam S, Chen N, Guerette B, Mulani P, Chao J. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. Can J Gastroenterol 2011;25:419-25. [PMID: 21912766 DOI: 10.1155/2011/724813] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 4.1] [Reference Citation Analysis]
163 Magro F, Portela F, Lago P, Deus J, Cotter J, Cremers I, Vieira A, Peixe P, Caldeira P, Lopes H, Gonçalves R, Reis J, Cravo M, Barros L, Ministro P, Lurdes Tavares M, Duarte A, Campos M, Carvalho L; Portuguese Study Group of IBD (GEDII), Association of Portuguese Patients with IBD (APDI). Inflammatory Bowel Disease: A Patient’s and Caregiver’s Perspective. Dig Dis Sci 2009;54:2671-9. [DOI: 10.1007/s10620-008-0658-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
164 Saunders R, Torrejon Torres R, Konsinski L. Evaluating the clinical and economic consequences of using video capsule endoscopy to monitor Crohn's disease. Clin Exp Gastroenterol 2019;12:375-84. [PMID: 31496780 DOI: 10.2147/CEG.S198958] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
165 Louis E, Löfberg R, Reinisch W, Camez A, Yang M, Pollack PF, Chen N, Chao J, Mulani PM. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial. J Crohns Colitis 2013;7:34-43. [PMID: 22480772 DOI: 10.1016/j.crohns.2012.02.017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
166 Afzali A, Ogden K, Friedman ML, Chao J, Wang A. Costs of providing infusion therapy for patients with inflammatory bowel disease in a hospital-based infusion center setting. Journal of Medical Economics 2017;20:409-22. [DOI: 10.1080/13696998.2017.1285779] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
167 Rodríguez-Moranta F, Soriano-Izquierdo A, Guardiola J. [Current status of treatment of inflammatory bowel disease]. Cir Esp 2007;82:254-9. [PMID: 18021623 DOI: 10.1016/s0009-739x(07)71722-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
168 van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, Pierik M, van der Woude CJ, Romberg-Camps MJ. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut. 2014;63:72-79. [PMID: 23135759 DOI: 10.1136/gutjnl-2012-303376] [Cited by in Crossref: 311] [Cited by in F6Publishing: 289] [Article Influence: 31.1] [Reference Citation Analysis]
169 Ha C, Mathur J, Kornbluth A. Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2015;9:497-505. [PMID: 25600263 DOI: 10.1586/17474124.2015.983079] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
170 Liu JJ, Wong K, Thiesen AL, Mah SJ, Dieleman LA, Claggett B, Saltzman JR, Fedorak RN. Increased epithelial gaps in the small intestines of patients with inflammatory bowel disease: density matters. Gastrointest Endosc. 2011;73:1174-1180. [PMID: 21396639 DOI: 10.1016/j.gie.2011.01.018] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
171 Punekar YS, Sunderland T, Hawkins N, Lindsay J. Cost-Effectiveness of Scheduled Maintenance Treatment with Infliximab for Pediatric Crohn's Disease. Value in Health 2010;13:188-95. [DOI: 10.1111/j.1524-4733.2009.00658.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
172 Loftus EV Jr, Skup M, Ozbay AB, Wu E, Guérin A, Chao J, Mulani P. The impact of moderate-to-severe Crohn's Disease on employees' salary growth. Inflamm Bowel Dis 2014;20:1734-8. [PMID: 25054337 DOI: 10.1097/MIB.0000000000000133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
173 Leung Y, Geddes M, Storek J, Panaccione R, Beck P. Hematopoietic cell transplantation for Crohn’s disease; is it time? World J Gastroenterol 2006; 12(41): 6665-6673 [PMID: 17075981 DOI: 10.3748/wjg.v12.i41.6665] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
174 Panaccione R, Sandborn WJ. Medical therapy of Crohn disease: . Current Opinion in Gastroenterology 2004;20:351-9. [DOI: 10.1097/00001574-200407000-00009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
175 Legnani P, Kornbluth A. Newer therapies for inflammatory bowel disease. Curr Treat Options Gastro 2004;7:161-7. [DOI: 10.1007/s11938-004-0037-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]